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Myo-inositol 1,3,4,5_tetrakisphosphate [Ins(1,3,4,5)P,] acts as a full agonist for Ca” release in saponin-permeabilised SH-SYSY neuroblastoma 
cells. Studies were conducted in the presence of myo-inositol hexakisphosphate (InsP,, 10 BUM), to inhibit the Ins( 1,3,4,5)P,-3-phosphatase catalysed 
back conversion of Ins(l,3,4,5)P, to Ins(lfl,S)P,. HPLC anaiysis confirmed that Ins(l,3,4,5)P, releases the entire content of Ins(l,4,5)P,-sensitive 
intra~Ilular Ca2* stores, independent of 3-phosphate activity. Further we utilised racemic myo-inositoll,4,5-t~sphosphat~3-phosphorothioate 
[m-Ins(l,3,4,5)P,-3S], anovel intrinsically Ins(l,3,4,5)P~-3-phosphatase resistant Ins(l,3,4,5)P, analogue. DL-Ins(1 ,3,4,5)P,-3S specifically displaced 
[‘H]Ins(l,4,5)P, from bovine adrenal cortex Ins(1,4,5)P, binding sites (IC,, = 889 nM, compared to Ins(1,4,5)P,, ICs, = 4.4 nM and Ins(1,3,4,5)P,, 
I&, = 152 nM). m.-Ins(l,3,4,5)P,-3S was a full agonist for Ca2’ release (EC% = 4.7 PM), being 90- and 2-fold less potent than Ins(1,4,5)P, and 
Ins(l,3,4,5)P, (with InsP,), respectively. DL-Ins( 1,3,4,5)P.,-3S will be an important ool for identification of potentially exclusive Ins(l,3,4,5)P., second 
messenger functions, since its resistance to 3-phosphatase action precludes the inconvenient artefact of steady state Ins(1,4,5)P, generation. 
Inositol 1,3,4,5-tetrakisphosphate nalogue; Calcium mobi~~ation; Ins(l,4,5)P, receptor; SH-SYSY celt; Inositol 1,3,4,5-tetrakispbosphate-3- 
phosphatase 
Many cell surface receptors activate phosphoinositi- 
dase C via G-proteins, which catalyse the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate to produce the 
second messengers, Ins(l,4,5)P, (Fig. 1 (1)) and dia- 
cylglycerol [ 11. Ins( 1,4,5)P, interacts specifically with a 
family of Ins( 1,4,5)P, receptor-operated Ca2’ channels 
to mobilise non-mitochondrial intracellular Ca2+ stores 
[l, 21. Ins( 1,4,5)P, is rapidly metabolised by S-phosphat- 
ase and 3-kinase activities to form Ins(l,4)P, and 
Ins(l,3,4,5)P~, respectively (Fig. 1 (2)) [3]. Considerable 
controversy exists as to whether Ins(1,3,4,5)P, possesses 
an independent or accessory second messenger ole. 
*Corresponding author. Fax: (44) (533) 523 996. 
Abbreviutiom myo-Inositol 1,4,5-&phosphate. Ins(l,4,5)P,; myo- 
Inositol 1,3,4,5_tetrakisphosphate, Ins(1,3,4,5)P,; myo-Inositol hexa- 
kisphosphate, InsP,; L-chiro-inositol 2,3,5-trisphosphorothioate, L- 
chiro-Ins(2,3,5)P&; oL-myo-inositol 1,4,5-trisphosphate-3-phospho- 
rothioate, m-Ins(1,3,4,5)P,-3s; myo-Inositol 1,4,5trisphosphate re- 
ceptor, IP,R; calcium, Ca *+* HEPES, rl-(Zhydroxylethyl)- 1piperazi- , 
n~than~ulfonic acid; EGTA, ethylene glycol-big-a~n~thyl ether 
N,NJ’,M-tetraacetic acid, HPLC, high performance liquid chroma- 
tography. 
Some evidence suggests that Ins(l,3,4,5)P~ may modu- 
late in calcium entry across the plasma membrane (re- 
viewed [4-6]), indeed Ins( 1,3,4,5)P,-activated Ca2’ 
channels have been recently identified in the plasma 
membrane of endothelial cells [7] and Ins(1,3,4,5)P,- 
activated Ca2+ mobilisation has been observed using 
crude microsomes and enriched vesicular plasma mem- 
branes prepared from T-lymphocyte and monocyte cell 
lines [8]. 
Furthermore, Ins(1,3,4,5)P, can apparently directly 
mobilise intracellular Ca2” stores, in cerebellar [9] and 
adrenal [lo] twosomes, ~cro~j~t~ Xe~o~~ oocytes 
[ 1 l] and permeabilised SH-SYSY neuroblastoma cells 
[ 12, 131, contradicting earlier reports that suggested that 
Ins( 1,3,4,5)P, failed to affect intracellular Ca2’ stores or 
modulate Ins( 1,4,5)P,-induced Ca2’ mobilisation [8,14- 
161. However, categorical interpretation of these studies 
may have been complicated by a number of factors, 
notably Ins( 1,4,5)P, contamination of the Ins( 1,3,4,5)P, 
[ 13,171 and evidence that endogenous 3-phosphatase ac- 
tivity in the cells was producing steady state generation 
of Ins(1,4,5)P, from exogenous Ins(1,3,4,5)P, [18,19]. 
Si~fi~ntly, Ins( 1,3,4,5)P, 3-phosphatase activity has 
only been detected in vitro in broken and permeabilised 
cells, or purified enzyme preparations [3,20]. It has re- 
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cently become apparent that both Ins(1,3,4,5,6)P, and 
InsP, potently inhibit Ins(1,3,4,5)P, 3-phosphatase ac- 
tivity 121,221. Thus, considering the endogenous cellular 
concentration range of Ins(l,3,4,5,6)P~ and InsP, (5 FM 
to 60 PM) [23,24], there is probably negligible Ins- 
(1,3,4,5)P, 3-phosphatase activity in intact cells [21,22]. 
We have recent used the low intrinic activity partial 
agonist, L-chiro-Ins(2,3,5)PS,, to provide compelling ev- 
idence that Ins(l,3,4,5~P~ is a weak but full agonist at 
the Ca2’ mobilising Ins( 1,4,5)P, receptor (IP,R) of sap- 
onin-permeabilised SH-SYSY cells [25,26]. Here utili- 
sing HPLC analysis of Ins( 1,3,4,5)P,-metabolism in per- 
meabilised SH-SYSY cells, we have confirmed that the 
limited 3-phosphatase activity present could be totally 
suppressed by inositol hexakisphosphate (InsP,) or by 
conducting the experiment at 4°C. This suggests that 
Ins(1,3,4,5)P, can release the entire content of Ins- 
(1,4,5)P,-sensitive intracellular Ca” stores, independent 
of detectable 3-phosphatase catalysed Ins( 1,4,5)P, gen- 
eration. Furthermore, we demonstrate that the novel 
intrinsically Ins(l,3,4,5)P~-3-phosphatase resistant Ins- 
(1,3,4,5)P, analogue, m-myo-inositol 1,4,5trisphos- 
phate-3-phosphorothioate [m=Ins(1,3,4,5)P,-3S, (3, 
Fig. l.)] is also a weak full agonist at the Ca2’ mobil- 
ising IP,R of saponin-permeabilised SH-SYSY cells. 
2. EXPERIMENTAL 
2.1. Materials 
The following reagents were used; 45CaCl, (approximately 1,000 
Cilmmol, Amersham, UK), [‘H]Ins(l,3,4,5)P, (45 Ciimmol, Amers- 
ham, UK). Disodium ATP, fitra-2, carbachol and EGTA were from 
Sigma (UK), all other reagents were of the highest purity available. 
nt,-Ins(l,3,4,5)P,-3S was synthesised from 3-O-propenyl-2,6di-U- 
benzyl-myo-inositol (prepared by isomerisation of the corresponding 
3-O- ally1 derivative [27]) by trisphosphorylation using a P(II1) ap- 
proach [28], followed by removal of the propenyl group and thio- 
phosphorylation [29] at the 3-position followed by deblocking using 
sodium in liquid ammo~a [29] and portion by ion exchange 
chromatography on Q-Sepharose Fast Flow using a gradient of trieth- 
ylammonium bicarbonate. Ins(1,3,4,5)P,-3S was quantified by Briggs 
phosphate assay and was used as its triethylammonium salt. Full 
synthetic details will be published elsewhere. Chemically synthesised 
Ins(l,4,5)P, [30] and Ins(1,3,4,5)P, [31] as Ksalts, were obtained from 
the University of Rhode Island Foundation Chemistry Group, USA. 
Both compo~ds were extensively character&d by “P- and ‘H-NMR, 
and found to be >99% pure with no other detectable inositol poly- 
phosphate contaminants. 
2.2. Cell culture 
SH-SYSY human neuroblastoma cell monolayers (passage 70-90), 
initially a gift from Dr. J.L. Biedler (Sloane-Kettering Institute, New 
York, USA) were su~~tu~ and ma~t~ned, as described 1321, ex- 
cept that the culture media was supplemented with 10% (v/v) new-born 
calf serum (Gibco, UK). 
2.3. “C2+-mobilisation assays 
43Ca2+-mobilisation assays were conducted using saponin-permea- 
bilised SH-SYSY cell at 20-22’C as previously described [25]. Each 
experiment was performed in duplicate with ionomycin (10 pM, free 
acid, Calbiochem, UK) to define the total releasable “Ca2+ pool and 
Ins( 1,4,5)P, (20-30 PM) to define the Ins( 1,4,5)P,-sensitive “‘Ca2’ 
pool, included as internal standards. 
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2.4. Preparation and analysis of HPLC samples 
SH-SYSY cells were prepared exactly as for the 45Ca2c release assay 
in CLB or CLB supplemented with InsP, (10 PM), however, 4sCaZ’ 
was replaced by an identical ~n~ntration of Ca’+. On completing the 
15 min loading period, lOOy1 of the permeabilised cell suspension was 
added to 100 ,& of CLB (+ InsP,, 10 FM) containing 3 PM 
Ins(l,3,4,5)P, spiked with [‘H]Ins(l,3,4,5)P, (6.7 nM or 30 nCi per 
tube) in 1.5 ml microcentrifuge tubes. The cells were allowed to incu- 
bate for 2 mm, and terminated by the addition of 7% (w/v) ice-cold 
perchloric acid. Boiled cells were included as an appropriate control. 
separation of samples and HPLC analysis of the inositol poly- 
phosphates was performed as previousiy described [33], 5 ml of Flo- 
Stint IV (Canberra Packard, UK) was added to each sample and 
vortexed, prior to scintillation counting. 
2.5. Binding studies 
Preparation of bovine adrenal cortices and the [3H]Ins(l,4,5)P, 
binding and displa~ent assays were performed as described f34]. 
Bound and free [3H]Ins(l,4,S)P, were separated by rapid filtration 
through Whatman GFlB glass fibre titers after incubation for 30 min 
at 4°C. Non-specific binding (approximately 150 dpm/assay) was 
defined by addition of 10 flM Ins(l,4,5)P,. Specifically bound 
[HjIns(l,4,5)P, (approximately 2,500 dpm/replicate) was readily dis- 
placed by Ins( 1,4,5)P,. 
2.6. Data analysis 
EC,, and IC,, values (concentrations producing half maximal stim- 
ulation and inhibition, respectively) and slope factors were estimated 
by computer assisted curve fitting using GraphPad INPLOT version 
3.1 (GraphPad Software, USA). Combined data from the independent 
experiments were expressed as mean + S.E.M., where n 5.3. 
3. RESULTS AND DISCUSSION 
3.1. HPLC studies 
HPLC analysis of the boiled cell preparations re- 
vealed a small quantity of conta~nating Ins(l,3,4)P, 
(1.4%) and Ins(1,4,5)P, (1.2%) present in the rI?IjIns- 
(1,3,4,5)P, (n = 3). In control preparations from sap- 
onin permeabilised SH-SYSY cells allowed to incubate 
for 2 min with -6.7 nM [3w]Ins( 1,3,4,5)P, and 3 PM Ins- 
(1,3,4,5)P, only 1.7% was metabolised to [3HjIns (1,4,5)P, 
and 6.8% to [3H]Ins(1,3,4)P, (n = 3). The addition of 
InsP, (10 PM) completely obliterated Ins(1,3,4,5)P,-3- 
phosphatase catalysed generation of [3H]Ins( 1,4,5)P, 
(1 .l%, n = 2) and also inhibited [3H]Ins( 1,3,4)P, genera- 
tion (2.2% n = 2). No inositol bisphosphate peaks were 
detected above background (Fig. 2A). 
A more significant percentage of the [3H]Ins (1,3,4,5)P, 
was metabolised uring the 15 min incubations allowing 
more accurate assessment of the 3-phosphatase inhibi- 
tion by InsP,. In control permeabilised cells about 39% 
(n = 3) of the ~3H]Ins(l,3~4,5)P~ was metabolised with 
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Fig. 1. Structures of Ins(1,4,5)P,, Ins(l,3,4,5)P, and nL-Ins(l,3,4,5)P,- 
3s (only n-isomers are shown). (1) Ins(l,4,5)P,, R = H; (2) 
Ins(l,3,4,5)P,, R = PO:-; (3) Ins(1,3,4,5)P~-3S, R = PSO$-. 
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Fig. 2. HPLC analysis of the metabolism of Ins(1,3,4,5)P, (3 PM) spiked with [‘H]Ins(l,3,4,5)P, (60 nCi, i= 6.7 nM) in SH-SYSY cells at 20_22”C, 
after 2 min (A) and 15 min (B) incubations. The peak counts corresponding to the various inositol poly-phosphate isomers were determined and 
corrected for background counts. Data from typical experiments are shown expressed as DPM counts, as an estimation of relative metabolism 
of the [“H]Ins(1,3,4,5)P, added. Total counts recovered were in the range 25-26 x lo3 DPM. ‘H-labelled inositol bisphosphate isomers were not 
detected in the boiled cells or following the 2 min incubations. Permeabilised SH-SYSY cells were incubated with control CLB (o), CLB 
supplemented with InsP, (10 ,uM) (A) or boiled prior to incubation in control CLB (o), see section 2 for further details. Inositol polyphosphates 
are numbered as indicated: (1) Ins(1,3,4,5)P,, (2) Ins(l,4,5)P,, (3) Ins(1,3,4)P,, (4) Ins(3,4)P,, (5) Ins(l,4)P, and (6) Ins(l,3)P,. 
32% appearing as [3H]Ins(l,3,4)P3 and 3% as [3H] 
Ins(1,4,5)P,. Additionally, a small amount of label was 
detected in the major InsP, isomers (Fig. 2B). The InsP, 
treated cells exhibited a similar total metabolism (37%, 
n = 3), however the 3H-label appeared predominantly as 
[3H]Ins( 1,3,4)P, (33%) and its metabolites Ins( 1,3)P, 
and Ins(3,4)P,, no significant counts were detected in 
the eluted fractions normally corresponding to [3H]Ins 
(1 ,4,5)P3 or [3H]Ins( 1,4)P,. These data suggest hat even 
after 15 min, InsP, (10 PM) completely inhibits 3-phos- 
phatase back-conversion of Ins( 1,3,4,5)P, to Ins( 1,4,5)- 
P3 in our saponin permeabilised SH-SYSY cells. Since 
our Ca2+-mobilisation assays involve the exposure of 
permeabilised cells r: 2 min at 20-22°C the inclusion 
of InsP, (10 ,uM) in the CLB insures that steady state 
generation of contaminating Ins( 1 ,4,5)P3 will be negligi- 
ble. InsP, has no intrinsic Ca2’ mobilising ability at 
concentrations up to 100 ,uM, nor does InsP, (10 ,uM) 
significantly shift the Ins( 1,4,5)P,-concentration re- 
sponse curve [25]. 
The metabolism of Ins(1,3,4,5)P, to Ins(1,3,4)P,, cat- 
alysed via Ins(l,4,5)P,/Ins( 1,3,4,5)P,-5-phosphatase i o- 
enzymes is well characterised, but recently active Ins- 
(1,3,4,5)P,-3-phosphatase catalysed metabolism of Ins 
(1,3,4,5)P, to Ins(1,4,5)P, has been detected in several 
cells and tissues, including saponin permeabilised SH- 
SYSY cells [3,12]. Since Ins(1,4,5)P, exhibits a more 
potent intrinsic activity for Ca2+ mobilisation, 3-phos- 
phatase catalysed generation of contaminating Ins- 
(1 ,4,5)P3 from exogenous Ins( 1,3,4,5)P, should produce 
a leftward shift of the Ins(1,3,4,5)P, concentration re- 
sponse curve. Indeed the ECS,, of Ins( 1,3,4,5)P,-induced 
Ca2’ release in SH-SYSY cells was shifted from 0.89 to 
2.54 ,uM in the presence of 10 ,uM InsP, [25], and a 
similar EC& value (2.05 yM) was obtained Ins- 
(1,3,4,5)P,-induced Ca2’ mobilisation was conducted at 
4°C to inhibit total cellular metabolism [26]. 
Significant Ins( 1,3,4,5)P,-3-phosphatase activity has 
only been observed in permeabilised cells and not in 
intact cell preparations [3]. Indeed Ins(1,3,4,5)P,-3- 
phosphatase activity may not be physiologically rele- 
vant since the inositol pentakisphosphate (InsP,) iso- 
mers and InsP, which are present in cells at 5-60 PM 
[23,24], inhibit Ins(1,3,4,5)P,-3-phosphatase with II, val- 
ues I 60 nM and I 3 nM respectively [22,35]. In fact 
InsP, isomers and InsP, are apparently the physiologi- 
cal substrates for the enzyme and their K, values have 
been estimated using purified rat liver 3-phosphatase 
at 40 nM and 0.3 nM, respectively [35]. Thus 
Ins( 1,3,4,5)P,-3-phosphatase activity is probably an ar- 
tefact which develops only when InsP, isomers and 
InsP, have been sufficiently diluted by experimental 
procedures, such as the detergent permeabilisation and 
centrifugation washing steps used during our 45Ca2+- 
release assays. 
There are a number of metabolic precedents indicat- 
ing that inositol polyphosphates can perturb the metab- 
olism of other inositol polyphosphates; Ins(3,4,5,6)P4 
potently inhibits Ins(1,3,4)P, 6-kinase [36], while Ins- 
( 1,3,4,5,6)P5 and InsP, also inhibit Ins(1 ,4,5)P3/Ins- 
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(1,3,4,5)P,-5-phosphatase activity with 50% inhibition 
occurring at 10-20 PM [35]. Indeed, we saw some evi- 
dence for InsP, inhibition of 5-phosphatase metabolism 
in our 2 min, but not the 15 min Ins( 1,3,4,5)P, HPLC 
study. Perhaps the inclusion of InsP, and InsP, isomers 
at appropriate physiological concentrations hould be 
an important consideration for the design of any ‘cytosol 
like’ buffers used for inositol polyphosphate studies. 
3.2. “Cd+-mobilisation and binding studies 
Ins(1 ,4,5)P3 mobilised about 70% of pre-loaded 
45Ca2+ from saponin-permeabilised SH-SYSY cells at 
20-22°C with an EC&, of 52 nM. We have recently 
shown Ins(1,3,4,5)P, was able to mobilise the entire 
Ins( 1,4,5)P,-sensitive intracellular calcium store of sap- 
onin-permeabilised SH-SYSY with an EC,,, of 879 nM, 
and that the ECso value was significantly increased in 
the presence of 10 PM InsP, (EC& = 2536 nM) [25]. 
Here our HPLC data confirm that the decreased po- 
tency of exogenous Ins(1,3,4,5)P4 in the presence of 
InsP,, was due to inhibition of 3-phosphatase catalysed 
steady state generation of Ins( 1,4,5)P,. 
To assess further our hypothesis that Ins( 1,3,4,5)P, is 
a weak but full agonist acting directly on the IP3R we 
synthesised a novel intrinsically 3-phosphatase resistant 
Ins( 1,3,4,5)P, analogue; or_-Ins(l,3,4,5)P,-3s. m-Ins- 
(1,3,4,5)P,-3S was able to fully displace [3H]Ins( 1,4,5)P, 
from bovine adrenal cortex membranes (IC5,, = 
889 nM), but it was considerably less potent than 
Ins( 1,4,5)P, (200-fold) and slightly less potent than Ins- 
(1,3,4,5)P, (5-fold) (Table I, Fig. 3). DL-Ins( 1,3,4,5)P,-3S 
was also a weak but full agonist for Ca” mobilisation 
in saponin permeabilised SH-SYSY cells (EC5,, = 4.6 
FM). m-Ins(1,3,4,5)P,-3S was much weaker agonist 
Table I 
The bovine adrenal cortex IP,R binding and permeabilised SH-SYSY 
cell 45CaZ’ release profiles of Ins(l,4,5)P,, DL-Ins(1,3,4,5)P,-3S and 
Ins( 1,3,4,5)P, 
Inositol polyphosphate IGo (nM) ECSo (nM) 
Ins( 1,4,5)P, 4.4 zt 0.1 52 + 2” 
Ins( 1,4,5)P, + InsP, (10 PM) _ 58 + 6” 
Ins(l,3,4,5)P, 152 f 4.4 819 + 92 
Ins(l,3,4,5)P, + InsP, (10 ,uM) _ 2536 + 303a,* 
DL-Ins(l,3,4,5)P,-3S 889.7 f 52.1 464lk 516 
oL_Ins(l,3,4,5)P,-3S + InsP, (10 ,uM) - 3534 f 429 
(i) IC,, estimates (nM) for binding athnity obtained via inositol poly- 
phosphate displacement of specific [‘H]Ins(l,4,5)P, from Ins(1,4,5)P,- 
binding sites on bovine adrenal cortex membranes. Results are shown 
as mean f S.E.M. (n 2 3); see section 2 for further details. (ii) EC,, 
estimates (nM) for inositol polyphosphate-induced 45CaZ+ mobilisa- 
tion in saponin permeabilised SH-SYSY cells at 2&22”C. Results are 
shown as mean f S.E.M. (n > 4); see section 2 for further details. 
“The ECSo values for Ins(1,4,5)P,- and Ins(l,3,4,5)P,-induced Ca” 
release have been previously reported [25] and are included here for 
comparison. Note only the Ins(1,3,4,5)P, concentration response 
curve was significantly shifted by InsP, (10,~M) (*) indicates 
P < 0.05.). 
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Fig. 3. Displacement of specific [‘H]Ins(l,4,5)P, binding by Ins(1,4,5)- 
P,-, DL-Ins(l,3,4,5)P,-3S and Ins(l,3,4,5)P, from bovine adrenal cortex 
membranes Ins(l,4,5)P, binding sites. Data indicate the percentage 
displacement of speciIic of [-‘H]Ins( 1,4,5)P, binding by increasing con- 
centrations of Ins(l,4,5) (m), Ins(l,3,4,5)P., (r> and DL- Ins(l,3,4,5)P,- 
3S (0). Results are shown as mean + S.E.M. of 3-4 experiments. 
Non-specific binding was defined using 10 PM Ins(l,4,5)P, (100% 
displacement); see section 2 for further details. 
than Ins( 1 ,4,5)P3 (90-fold), but its action was only 2-fold 
less potent than Ins(1,3,4,5)P, in the presence of InsP, 
(Table I, Fig. 4). Additionally, the ECso of DL- 
Ins(1,3,4,5)P,-3S was not significantly shifted in the 
presence InsP, (10 PM) which our HPLC studies had 
shown completely obliterates 3-phosphatase activity 
(Table I, Fig. 4). This was wholly expected because the 
3-position phosphorothioate group should be intrinsi- 
cally resistant to Ins( 1,3,4,5)P,-3-phosphatase activity, 
just as the 5-phosphorothioate groups of inositol 1,4,5- 
trisphosphorothioate and inositol 1 ,Cbisphosphate 5- 
phosphorothioate were resistant o Ins( 1,4,5)P,-5-phos- 
phatase activity [37]. In contrast, the concentration re- 
sponse curve of Ins( 1,3,4,5)P, [but not Ins(1 ,4,5)P3] was 
significantly shifted to the right by InsP, [25] (Table I). 
Although m-Ins(l,3,4,5)P,-3S is a racemic mixture, the 
L-isomer is very probably inactive, because the IP,R 
displays stringent stereospecificity with L-Ins( 1,4,5)P, 
[3840] and L-Ins( 1,3,4,5)P, [26] both exhibiting exceed- 
ing poor ligand and agonist profiles. 
Ins( 1,3,4,5)P, and Ins( 1,3,4,5)P,-3S possess all the 
critical structural motifs requisite for effective interac- 
tion with the Ins(l,4,5)P,-receptor [41,42], and we pro- 
pose that the respective addition to Ins(1,4,5)P, of a 
3-phosphate or 3-phosphorothioate group, simply pro- 
duces a weaker ligand and agonist at the IP,R in SH- 
SYSY cells. Being the first 3-phosphatase resistant 
Ins( 1,3,4,5)P, analogue, Dr.,-Ins( 1,3,4,5)P,-3S will be a 
crucial tool for probing and contirming exclusive sec- 
ond messenger roles for Ins( 1,3,4,5)P,, since it precludes 
Volume 336, number 2 FEBS LETTERS December 1993 
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Fig. 4. Ins(1,4,5)P,- and or-Ins(1,3,4,5)P,-3Sinduced Ca2+ release. 
Data indicates the percentage of 45Ca2+ released at 2&22”C from the 
intracellular Ins(l,4,5)P,-sensitive Ca2+ stores of saponin permeabil- 
ised SH-SYSY cells in the presence of increasing concentrations of 
Ins(1,4,5) (m), oL-Ins(1,3,4,5)P,-3S (0) and DL-Ins(1,3,4,5)P,-3S + 
InsP, (10 PM) (0). Results are shown as mean + S.E.M. error of four 
experiments. Maximal Ca” release from intracellular Ins(1,4,5)P,- 
sensitive Ca*+ stores was defined using an internal standard of 30 PM 
Ins(1,4,5)P, (100% release); see section 2 for a complete description. 
the complication of steady state generation of contami- 
nating Ins( 1,4,5)P,. Here DL-Ins( 1,3,4,5)P,-3s has been 
used to confirm that Ins(1,3,4,5)P, independently mo- 
bilises intracellular Ca2’ via the IP,R in SH-SYSY cells. 
However, rx-Ins( 1,3,4,5)P,-3s should be even more 
uniquely suited to the investigation of the putative role 
of the various ‘Ins( 1,3,4,5)P, receptors’ (reviewed [43]) 
in processes uch as Ca2+ entry across the plasma mem- 
brane [5]. 
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